Eisai to Divest Rights for Anti-Epileptic Drug Fycompa (perampanel) CIII in United States to Catalyst Pharmaceuticals

TOKYO, Dec 20, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that it has entered into an agreement to transfer the United States (U.S.) commercial rights for the anti-epileptic drug (AED) Fycompa (generic name: perampanel) CIII to Catalyst Pharmaceuticals, Inc., as well as to provide Catalyst Pharmaceuticals with an exclusive negotiation […]

Asian and Pacific Countries Adopt Jakarta Declaration 2023-2032

JAKARTA, Oct 24, 2022 – (ACN Newswire via SEAPRWire.com) – The ‘High-level Intergovernmental Meeting on the Final Review of the Asian and Pacific Decade of Persons with Disabilities’ (HLIGM APDPD) closed on Friday (Oct 21) with 53 Asia-Pacific and 9 associated countries adopting the landmark Jakarta Declaration, marking the start of the fourth ‘Asian and […]

Eisai Inc. Collaborates with C2N to Build Awareness and Real-World Evidence for Blood-based Assays

TOKYO, Aug 24, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that its U.S. subsidiary Eisai Inc. has entered into a memorandum of understanding with C2N Diagnostics (“C2N”) that will seek to build awareness about how blood-based assays in the diagnosis for people living with cognitive impairment, including Alzheimer’s disease (AD), […]

Intelligent Living Application Group Inc. Announces Closing of $20.24 Million Initial Public Offering

Hong Kong, July 15, 2022 (GLOBE NEWSWIRE via SEAPRWire.com) — Intelligent Living Application Group Inc. (Nasdaq: ILAG) (the “Company” or “Intelligent Living”), a premium lockset manufacturer in Hong Kong, today announced the closing of its initial public offering (the “Offering”) of 5,060,000 ordinary shares at a price of $4.00 per share. The aggregate gross proceeds […]

Intelligent Living Application Group Inc. Announces Pricing of $20.24 Million Initial Public Offering

Hong Kong, July 12, 2022 (GLOBE NEWSWIRE via SEAPRWire.com) — Intelligent Living Application Group Inc. (the “Company” or “Intelligent Living”), a premium lockset manufacturer in Hong Kong, today announced the pricing of its initial public offering (the “Offering”) of 5,060,000 ordinary shares at a price of $4.00 per share. The ordinary shares have been approved […]

U.S. FDA Accepts and Grants Priority Review for Eisai’s Biologics License Application of Lecanemab

TOKYO, Jul 6, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and Biogen Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) under the accelerated approval pathway for lecanemab (development code: BAN2401), an investigational anti-amyloid beta (Abeta) protofibril antibody for the treatment of mild […]